Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 4 of about 4   

Articles published

NVO 43.81 -0.59 (-1.33%)
price chart
This Top-Performing Stock is Tackling One of the World's Deadliest Diseases
And when it comes to insulin, the market leader is undoubtedly Novo Nordisk A/S (NYSE:NVO), a global health care pharmaceutical company with more than 85 years in the market.
Related articles »  
Morning News: Z, DG, NVO, LVS, ADT, CAG, RAH, DDS, PLCE, STO, XOM, CS
Insulin maker Novo Nordisk A/S (ADR) (NYSE:NVO) reported positive data on its liraglutide-based therapy for type 2 diabetes.
Related articles »  
Novo Nordisk A/S: Catching The Increasing Diabetes Trend
Based on the data gathered from MorningStar, NVO's key stats will be compared to its peers in the biotechnology industry within the healthcare sector, including Bristol-Myers Squibb Company (NYSE:BMY), Eli Lilly and Company (NYSE:LLY), and Sanofi ADR ...
Related articles »  
China Drug Market to Boom � Diabetes Alone a $3.2 Billion Business by 2016
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. This article appears in: investing , Stocks.
Related articles »